Title: Chief of Neuropsychopharmacology Section
Company: National Institute on Drug Abuse, U.S. National Institutes of Health
Location: Baltimore, Maryland, United States
Eliot Gardner, Chief of Neuropsychopharmacology Section at National Institute on Drug Abuse, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in research on addictive drugs.
Dr. Gardner’s many scholarly degrees include a Bachelor of Arts in psychology from Harvard University in Cambridge, Massachusetts and a Master of Arts in experimental psychology and psychopharmacology and a Doctor of Philosophy in physiological psychology from McGill University in Montreal, Quebec, Canada. Additionally, he served postdoctoral fellowships in pharmacology and neurology from the Albert Einstein College of Medicine in New York. He served his country for three years with the United States Air Force as a medical research officer with the School of Aerospace Medicine.
Dr. Gardner has excelled as a faculty member with Albert Einstein College of Medicine for over three decades and since 2000 has provided superior service as chief of neuropsychopharmacology section of the National Institute on Drug Abuse with the National Institutes of Health. In this capacity, his research includes basic brain mechanisms underlying drug addiction, craving, and relapse; endocannabinoid brain mechanisms and addiction; slow-onset long-acting dopamine transport inhibitors; and drugs acting on the endocannabinoid brain system. He has published numerous paper and articles in peer-reviewed journals on drug addiction.
Dr. Gardner has accrued numerous honors for his research that include a Lifetime Achievement Award, from the International Cannabinoid Research Society (ICRS), a Lifetime Achievement Award from the International Drug Abuse Research Society and a Brain Research Pioneer Award from the Winter Conference on Brain Research in 2020.
To remain aware of changes and advancements in his field, Dr. Gardner maintains affiliation with the Society for Neuroscience, American Society of Addiction of Medicine, Canadian Society of Addiction Medicine, International Society of Addiction Medicine, American Academy of Addiction Psychiatry, International Drug Abuse Research Society and the International Cannabinoid Research Society.
Dr. Gardner attributes his success to his family and his passion for his work. As career highlights, he cites receiving the Lifetime Achievement Awards from the International Cannabinoid Research Society (ICRS) and the International Drug Abuse Research Society as well as the Brain Research Pioneer Award from the Winter Conference on Brain Research. In coming years, he hopes to continue his work in the pharmacology field to find better treatments and develop better medications for addiction. Additionally, he hopes to continue his research on cannabis and cannabinoids, given that recently cannabis has been decriminalized and legalized all over the world.
Contact Dr. Gardner: